Genomic Characterization of ESBL/AmpC-Producing Escherichia coli in Stray Dogs Sheltered in Yangzhou, China

Figures & data

Table 1 Antimicrobial Resistance Profiles of 80 Cefotaxime-Resistant Escherichia coli Isolates

		Resistance % (No. of Resistant Isolates)
Antibiotics	MIC Breakpoint µg/mL	Feces (n = 59)	Environment (n = 21)	Total (n = 80)
Ampicillin	≥32	100.0 (59)	100.0 (21)	100.0 (80)
Cefazolin	≥8	25.4 (15)	23.8 (5)	25.0 (20)
Cefotaxime	≥4	100.0 (59)	100.0 (21)	100.0 (80)
Meropenem	≥4	0 (0)	0 (0)	0 (0)
Gentamicin	≥16	25.4 (15)	9.5 (2)	21.3 (17)
Amikacin	≥64	0 (0)	0 (0)	0 (0)
Streptomycin	≥64	25.4 (15)	23.8 (5)	25.0 (20)
Tetracycline	≥16	81.4 (48)	85.7 (18)	82.5 (66)
Tigecycline	≥1	0 (0)	0 (0)	0 (0)
Nalidixic acid	≥32	32.2 (19)	28.6 (6)	31.3 (25)
Ciprofloxacin	≥1	28.8 (17)	19.0 (4)	26.3 (21)
Colistin	≥4	0 (0)	0 (0)	0 (0)
Trimethoprim-sulfamethoxazole	≥4/76	61.0 (36)	71.4 (15)	63.8 (51)
Chloramphenicol	≥32	32.2 (19)	47.6 (10)	36.3 (29)
Florfenicol	≥32	32.2 (19)	42.9 (9)	35.0 (28)
Fosfomycin	≥256	28.8 (17)	4.8 (1)	22.5 (18)

Abbreviation: MIC, minimum inhibitory concentration.

Figure 1 Antimicrobial resistance (AR) patterns of cefotaxime-resistant E. coli isolates from stray dog feces and the environment.

Figure 2 Distribution of ESBL/AmpC β-lactamase genes, sequence types (STs), and phylogroups in E. coli isolates.

Figure 3 Phylogenetic relationships between the 80 cefotaxime-resistant E. coli strains. The sequence type, serotype, source, resistance genes, and plasmid replicons for each strain are indicated on the right side of the tree.